Assignee
JOLLA PHARMA
US·32 granted patents·10 pending applications·952 citations·filing 1988–2015
Top patents by PatentIndex Score
42 records- 0197US5552391AChemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 1993·Granted Sep 3, 1996·160 cites·12 claims
- 0290US7351855B2Chemically defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 2003·Granted Apr 1, 2008·24 cites·143 claims
- 0389US6207160B1aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologiesJOLLA PHARMA·Filed 1996·Granted Mar 27, 2001·70 cites·25 claims
- 0489US5606047AChemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 1995·Granted Feb 25, 1997·65 cites·1 claims
- 0589US5276013AConjugates of biologically stable polyfunctional molecules and polynucleotides for treating systemic lupus erythematosusJOLLA PHARMA·Filed 1992·Granted Jan 4, 1994·59 cites·33 claims
- 0688US5817752ACyclic polypeptides comprising a thioether linkage and methods for their preparationJOLLA PHARMA·Filed 1996·Granted Oct 6, 1998·65 cites·23 claims
- 0786US8722111B2Modified pectins, compositions and methods related theretoJOLLA PHARMA·Filed 2013·Granted May 13, 2014·2 cites·34 claims
- 0886US8658224B2Modified pectins, compositions and methods related theretoJOLLA PHARMA·Filed 2013·Granted Feb 25, 2014·1 cites·19 claims
- 0985US6060056AComposition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform moleculeJOLLA PHARMA·Filed 1993·Granted May 9, 2000·58 cites·56 claims
- 1084US6951939B2Multivalent platform molecules comprising high molecular weight polyethylene oxideJOLLA PHARMA·Filed 2001·Granted Oct 4, 2005·18 cites·170 claims
- 1183US5874409AAPL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologiesJOLLA PHARMA·Filed 1995·Granted Feb 23, 1999·42 cites·2 claims
- 1283US5726329AModified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotidesJOLLA PHARMA·Filed 1995·Granted Mar 10, 1998·53 cites·11 claims
- 1383US5162515AConjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosusJOLLA PHARMA·Filed 1990·Granted Nov 10, 1992·40 cites·2 claims
- 1481US8877263B2Modified pectins, compositions and methods related theretoJOLLA PHARMA·Filed 2014·Granted Nov 4, 2014·2 cites·21 claims
- 1581US7163683B2Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform moleculeJOLLA PHARMA·Filed 2004·Granted Jan 16, 2007·9 cites·53 claims
- 1680US5633395AChemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 1995·Granted May 27, 1997·33 cites·1 claims
- 1779US7138244B2Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform moleculeJOLLA PHARMA·Filed 2004·Granted Nov 21, 2006·7 cites·17 claims
- 1879US6458953B1Valency platform molecules comprising carbamate linkagesJOLLA PHARMA·Filed 1999·Granted Oct 1, 2002·16 cites·37 claims
- 1978US5268454AComposition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrierJOLLA PHARMA·Filed 1991·Granted Dec 7, 1993·42 cites·11 claims
- 2077US9181354B2Modified pectins, compositions and methods related theretoJOLLA PHARMA·Filed 2014·Granted Nov 10, 2015·0 cites·14 claims
- 2176US5874552AModified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotidesJOLLA PHARMA·Filed 1995·Granted Feb 23, 1999·29 cites·18 claims
- 2274US6858210B1Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using sameJOLLA PHARMA·Filed 1999·Granted Feb 22, 2005·33 cites·104 claims
- 2373US7081242B1Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereofJOLLA PHARMA·Filed 2000·Granted Jul 25, 2006·9 cites·64 claims
- 2473US6410775B1APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologiesJOLLA PHARMA·Filed 1998·Granted Jun 25, 2002·18 cites·5 claims
- 2571US6031073ACyclic polypeptides comprising a thioether linkage and methods for their preparationJOLLA PHARMA·Filed 1997·Granted Feb 29, 2000·33 cites·6 claims
- 2670US7115581B2Chemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 2002·Granted Oct 3, 2006·1 cites·46 claims
- 2768US2015133399A1Composition and uses of galectin antagonistJOLLA PHARMA·Filed 2014·Application pending·0 cites
- 2866US7208156B2Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform moleculeJOLLA PHARMA·Filed 2002·Granted Apr 24, 2007·2 cites·11 claims
- 2966US2014148404A1Composition and uses of galectin antagonistsJOLLA PHARMA·Filed 2014·Application pending·0 cites
- 3064US2008293660A1Chemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 2008·Application pending·0 cites
- 3162US6399578B1Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using sameJOLLA PHARMA·Filed 1999·Granted Jun 4, 2002·21 cites·22 claims
- 3262US6166198AMethods for oligonucleotide synthesisJOLLA PHARMA·Filed 1998·Granted Dec 26, 2000·12 cites·79 claims
- 3359US2007191263A1Valency platform molecules comprising aminooxy groupsJOLLA PHARMA·Filed 2007·Application pending·0 cites
- 3457US2006229270A1Methods of treating proteinuria by reducing double-stranded DNA antibodiesJOLLA PHARMA·Filed 2006·Application pending·0 cites
- 3557US2016074465A1Methods for Treating HypotensionJOLLA PHARMA·Filed 2015·Application pending·0 cites
- 3654US2005226844A1Valency platform molecules comprising carbamate linkagesJOLLA PHARMA·Filed 2005·Application pending·0 cites
- 3750US2007078157A1Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseasesJOLLA PHARMA·Filed 2006·Application pending·0 cites
- 3849US4950469AD-GL conjugate therapyJOLLA PHARMA·Filed 1988·Granted Aug 21, 1990·12 cites·8 claims
- 3949US2005175620A1Multivalent platform molecules comprising high molecular weight polyethylene oxideJOLLA PHARMA·Filed 2005·Application pending·0 cites
- 4045US4950713AConjugates of D-glutamic acid: D-lysine copolymer and certain biochemicalsJOLLA PHARMA·Filed 1988·Granted Aug 21, 1990·9 cites·8 claims
- 4145US2006142229A1Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereofJOLLA PHARMA·Filed 2005·Application pending·0 cites
- 4241US5017648AD-GL conjugate therapyJOLLA PHARMA·Filed 1990·Granted May 21, 1991·7 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when JOLLA PHARMA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →